The single-dose pharmacokinetics of marbofloxacin was studied in clinically normal foals after intravenous and intramuscular administration of 5 mg of marbofloxacin/kg of body weight. Marbofloxacin concentrations were determined by microbiological assay method. The disposition of marbofloxacin was best described by a two-compartment open model after a single intravenous injection while, by a one-compartment open model after intramuscular administration. The distribution half-life, elimination half-life, mean residence time of marbofloxacin after intravenous injection were 0.27, 6.4, 6.8 h after 5 mg/kg dose. Following intramuscular administration, the drug absorbed at a fast rate as indicated by short absorption half-life (t 0.5(ab) ) of 0.26 h. The drug was eliminated at a slow rate with an elimination half-life t 0.5(el) of 7.16 h after 5 mg/kg dose. The extent of serum protein binding was 27.5%. These results indicate that a dose of 5 mg of marbofloxacin/kg administered as a single dose once daily could be useful in the treatment of diseases caused by sensitive pathogens in foals after specific assessments.
Introduction
Fluoroquinolones are antimicrobial drugs that generally have very good activity against a broad spectrum of aerobic gram-negative including Pasteurella spp., some gram-positive bacteria and against mycoplasma (Hannan et al., 1997) . Fluoroquinolones have other desirable characteristics such as large volumes of distribution, low serum protein binding and relatively low minimum inhibitory concentrations (MIC) against susceptible target microorganisms (Brown, 1996) . Marbofloxacin is a second generation fluoroquinolone (Martinez et al., 2006) approved exclusively for animal clinical use. It has broad spectrum bactericidal activity against Gram-negative bacteria, Gram-positive bacteria and Mycoplasma species (Drugeon et al., 1997; Meunier et al., 2004) . It has some pharmacokinetic properties such as a long elimination half-life (t 0.5(el) ), and high bioavailability after oral administration (Heinen, 2002) . The pharmacokinetics of marbofloxacin has been extensively investigated in adult donkeys (Gonzalez et al., 2007) and horses (Bousquet-Melou et al., 2002; Carretero et al., 2002; Peyrou et al., 2004) but no data are available in foals. Consequently, the purpose of the present study was to investigate the bioavailability and pharmacokinetics of marbofloxacin in foals following a single intravenous (IV) and intramuscular (IM) administration of 5 mg/kg of body weight.
Materials and Methods Drug
Marbofloxacin was used as a 10% injectable aqueous solution obtained from Veterinary Pharmaceutical Laboratories, France (Marbocyl ® , Vetoquinol, Lure, France). Marbofloxacin standard was provided by Vetoquinol (Lure, France).
Animals
Six clinically healthy male and female Egyptian foals weighing 200-250 kg b. wt. (9-11 months of age) were used. Animals were kept under good hygienic condition and none of them were treated with antibiotics for one month prior to the trial.
Experimental design
The foals were given a single intravenous (into the right jugular vein) and intramuscular (into the deep gluteal muscle of hindquarters) dose of 5 mg/kg 10% aqueous solution of marbofloxacin (Carpenter et al., 2009 ) with a two weeks washout period between each route. Blood samples were collected from the left jugular vein just before drug administration and at 0. 083, 0.167, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 hours after drug administration. The blood was allowed to clot at room temperature, and then the serum was separated by centrifugation at 3000 g for 15 minutes. Serum samples were stored at -20ºC until assayed. Three foals showed only slight swelling at the site of injection and diarrhea in one foal.
Drug assay
Marbofloxacin concentrations in serum samples were determined by the microbiological assay method described by Tsai and Kondo (2001) using Escherichia coli (ATCC 25922) as a test organism.
Standard curves were constructed using antibacterial-free serum collected from foals. Six wells, 8 mm in diameter were cut at equal distances in standard petri dishes containing 25 ml seeded agar. The wells were filled with 100 µl of either the test samples or marbofloxacin standards. The plates were incubated at 37ºC for 24 h. The inhibition zone diameters were measured and the marbofloxacin concentrations in the test samples were calculated from the standard curve. The limit of detection of the marbofloxacin assay was 0.02 ug/ml. Semi-logarithmic plots of the inhibition zone diameter versus standard marbofloxacin concentrations in serum were linear with typical correlation coefficient of 0.97. The extent of protein binding was determined in vitro according to the method described previously by Craig and Suh (1991) with marbofloxacin concentrations 0.02, 0.04, 0.08, 0.156, 0.313, 0.625, 1.25, 2.5 and 5 ug/ml in serum and phosphate buffered saline (pH 7.2). This method was based on the diffusion of free antibiotic into the agar medium. The differences in the diameters of the inhibition zones between the solutions of the drug in the buffer and serum samples were then calculated according to the following equation:
Protein binding % = (Zone of inhibition in buffer-Zone of inhibition in serum/ Zone of inhibition in buffer) x 100 Pharmacokinetic analysis Serum concentrations of marbofloxacin after IV and IM administrations were subjected to a compartmental analysis using a nonlinear least-squares regression analysis. The analysis was done with the help of a computerized curve-stripping software package (R STRIP, Version 5.0; Micromath Scientific Software, Salt Lake City, UT, USA). Data were examined by sequential weighted nonlinear regression. Mono-exponential and bi-exponential equations were fitted to individual serum concentration-time data. Akaike's Information Criterion (Yamaoka et al., 1978) , residual sum of squares, and analysis of the residual's plots were used to discriminate between models (Powers, 1990) . Following IV injection, the serum concentration-time relationship was best estimated as a two-compartment open model system (Baggot, 1978) according to the following bi-exponential equation: C p = Ae -αt + Be -βt , where C p is the concentration of drug in the serum at time t; A is the intercept of the distribution phase with the concentration axis expressed as µg/ml -; B is the intercept of the elimination phase with the concentration axis expressed as µg/ml; α is the distribution rate constant expressed in units of reciprocal time (h -1 ); β is the elimination rate constant expressed in units of reciprocal time (h -1 ); and e is the natural logarithm base. After IM administration, data was analyzed by adopting a one-compartment model. This program also calculated noncompartmental parameters using the statistical moment theory (Gibaldi and Perrier, 1982) . The C max (maximum serum concentration) and t max (time of maximum serum concentration) were obtained from individual tabulated values (observed values). The terminal elimination half-life (t 0.5(el) ) and absorption half-life (t 0.5(ab) ) were calculated as ln2/K el or ln2/K ab , respectively, where K el and K ab are the elimination and absorption rate constants, respectively. The area under serum concentration-time curve (AUC) and area under the first moment curve (AUMC) were calculated using the trapezoidal method and extrapolation to infinity (Baggot, 1978) . The mean residence time (MRT) was calculated as MRT = AUMC/AUC. The total body clearance (Cl B ) was calculated as Cl B = Dose/AUC and the absolute bioavailability (F) as F = AUC i.m /AUC i.v · 100 (Gibaldi and Perrier, 1982) . The results obtained were expressed as mean and standard error (SE). Standard errors were calculated from the mean data according to Snedecor and Cochran (1976) .
Pharmacodynamic analysis
Several pharmacodynamic (PD) parameters including the maximum serum concentration/minimum inhibitory concentration (C max /MIC) ratio and the area under the 24-h serum concentrationtime curve/MIC (AUC 0-24h /MIC) ratio have been proposed to predict the antimicrobial efficacy of fluoroquinolones in vivo (Turnidge, 1999; McKellar et al., 2004) . The PD efficacy of marbofloxacin was determined by calculating the C max /MIC and AUC/MIC ratios following IM administration using the hypothetical MIC 90 of marbofloxacin against Enterobacteriacae 0.027 µg/ml (BousquetMelou et al., 2002; Peyrou et al., 2004) .
Results
The mean serum concentration time courses of marbofloxacin after intravenous and intramuscular administration are depicted in (Fig. 1) . Pharmacokinetic parameters are showed in (Table 1) . After intravenous administration of 5 mg/kg b. wt., the marbofloxacin serum concentration time data fit twocompartment open model. The distribution half-life, elimination half-life, mean residence time of marbofloxacin after intravenous injection were 0.27, 6.4, 6.8 h. Following intramuscular administration, the drug absorbed at a fast rate as indicated by short absorption half-life (t 0.5(ab) ) of 0.26 h. The drug was eliminated at a slow rate with an elimination half-life t 0.5(el) of 7.16 h. The extent of serum protein binding was 27.5%. C p º concentration at zero time (immediately after single IV injection); A, B zero-time intercepts of the biphasic disposition curve; α, β hybrid rate constants representing the slopes of distribution and elimination phases, respectively; k 12 first-order constant for transfer from central to peripheral compartment; k 21 first-order constant for transfer from peripheral to central compartment; K el elimination rate constant; t 0.5(α) distribution half-life; t 0.5(β) elimination half-life; MRT mean residence time; AUC 0-24 area under serum concentrationtime curve; AUMC area under moment curve; Vc apparent volume of the central compartment; Vd ss volume of distribution at steady state; Cl B total body clearance. k ab firstorder absorption rate constant; C max maximum serum concentration; T max time to peak serum concentration; t 0.5(ab) absorption half-life; t 0.5(el) elimination half-life; MAT mean absorption time; F fraction of drug absorbed systemically after IM injection.
Discussion
Data on the pharmacokinetics of marbofloxacin in equines are limited, and specific pharmacokinetic data for foals are lacking. Therefore, foals were treated with marbofloxacin at the recommended dose of 5 mg/kg b. wt. either IV or IM. The study revealed that serum marbofloxacin concentrations versus time decreased in a bi-exponential manner following intravenous injection, demonstrating the presence of distribution and elimination phases and justifying the use of twocompartment open model. This finding is in agreement with other pharmacokinetic study of the drug in calves (Ismail and ElKattan, 2007) . Serum concentration profiles showed a rapid initial distributive phase, followed by a slower elimination phase with an estimated mean elimination half-life of 6.4 h. This finding is similar to that recorded for the drug in horse 7.56 h (Bousquet-Melou et al., 2002) . In this respect, fluoroquinolones have a long serum half-life making them suitable for once or twice a day administration (Vancutsem et al., 1990) . The distribution of marbofloxacin in the body of foals recorded in this study was more than unity (> one L/kg) following intravenous injection (2.3 L/kg), indicated that the drug was extensively distributed to extravascular tissues and this result supported by Baggot (1978) . In the present study, the total body clearance (Cl tot ) 0.34 L/kg / h agreed with that reported in horse 0.25 L/kg/h (Bousquet-Melou et al., 2002) . Following intramuscular administration, the drug absorbed at a fast rate as indicated by an absorption half-life (t 0.5(ab) ) of 0.26 h. The pharmacokinetic properties of fluoroquinolones include rapid absorption (Roland et al., 1995) . This may be due to the result of continued absorption of marbofloxacin from the site of intramuscular administration during the elimination phase, thereby, prolonging the t 0.5(el) of the drug. Absorption limits drug elimination (Gibaldi and Perrier, 1982) . The drug was eliminated at a slow rate with an elimination half-life t 0.5(el) of 7.16 h. Also, this result supported by longer MRT of 8.01 h. The systemic bioavailability of marbofloxacin after IM administration was 85.7% , similar to that reported in horse 87.9% (Carretero et al., 2002) . These values indicates high rate of absorption of the drug from that injection site. The in vitro protein binding tendency of marbofloxacin to foal's serum proteins was 27.5%. This indicated that the drug is slightly bound to serum proteins. It was stated that fluoroquinolones binding to serum proteins is relatively low up to 30% (Wise et al., 1984) .
The minimum inhibitory concentrations (MIC s ) of marbofloxacin against foal's bacterial isolates have not yet been determined. The MIC of the drug was recorded to be 0.027 ug ml -1 against Enterobacteriacae (Bousquet-Melou et al., 2002; Peyrou et al., 2004) . Fluoroquinolones are active against bacterial pathogens in a concentrationdependent manner. Various empirical PK/PD ratios have been proposed to predict the success or failure of therapy. The effective use of the fluoroquinolones against clinically important animal pathogens is dependent on designing dosages that attain serum C max /MIC ratios of 10:1 or AUC/MIC ratios of 125:1 (Walker, 2000; Toutain et al., 2002) . Marbofloxacin PK/PD integration after IM administration revealed values for C max /MIC and AUC/MIC ratios of 42.2 and 466.7 which indicate the excellent PD characteristics of the drug in foals.
The use of other fluoroquinolones has been associated with arthropathy in young animals of various species including foals (Vivrette et al., 2001) , thus additional studies are necessary to confirm that marbofloxacin does not cause arthropathy before its use can be recommended in foals.
In conclusion, a dose of 5 mg of marbofloxacin/kg administered as a single dose once daily could be useful in the treatment of diseases caused by Enterobacteriacae in foals. 
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